Tirzepatide consistently reduces bodyweight regardless of BMI before treatment, shows new analysis Dr. Kamal Kant Kohli25 March 2024 9:30 PM ISTTirzepatide, a medication authorised to treat obesity and/or type 2 diabetes, consistently reduces bodyweight regardless of the patient's body mass...
Tirzepatide reduces body weight and waist circumference in people with obesity regardless of duration of their condition: Study Dr. Kamal Kant Kohli20 March 2024 1:30 AM ISTNew research to be presented at this year's European Congress on Obesity (Venice, Italy, May 12-15) shows that the obesity medication tirzepatide...
Eli Lilly finds bacteria, other impurities in Mounjaro, Zepbound knockoffs Ruchika Sharma8 March 2024 5:48 PM ISTEli Lilly said on Thursday it has found bacteria and high levels of impurities in products claiming to be compounded versions of tirzepatide, the...
Eli Lilly gets CDSCO Panel Nod to Import, Market Antidiabetic Drug Tirzepatide solution for injection Single dose vial Dr. Divya Colin29 Feb 2024 6:00 PM ISTNew Delhi: The drug major Eli Lilly has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Eli Lilly expects to launch diabetes drug Mounjaro in India next year: CEO Ruchika Sharma29 Feb 2024 12:30 PM ISTMounjaro, chemically known as tirzepatide, is currently sold in the UK and Europe under the same brand name for both conditions.
Tirzepatide, novel agent for treating type 2 diabetes has different efficacy in Asians and non-Asians: Study Medha Baranwal27 Feb 2024 1:00 AM ISTChina: A recent meta-analysis published in Diabetes Therapy has shed light on the comparative safety and efficacy of tirzepatide in Asians and...
Weight loss medication tirzepatide may help lower BP in adults with obesity Dr. Kamal Kant Kohli10 Feb 2024 11:15 AM ISTThe new weight loss medication tirzepatide significantly lowered the systolic blood pressure (the top number in a blood pressure reading) for nearly...
Tirzepatide significantly lowers albuminuria across all administered doses in patients with type 2 diabetes: Study Medha Baranwal26 Dec 2023 8:45 AM ISTGreece: Tirzepatide, across all administered doses, probably leads to a significant reduction in albuminuria, while its use is linked with a neutral...
Tirzepatide may reduce CVD Risk in Non-Diabetic Overweight Patients Jacinthlyn Sylvia20 Dec 2023 9:30 PM ISTThe outcomes from the SURMOUNT-1 phase 3 trial found tirzepatide to effectively manage the long-term risk of atherosclerotic cardiovascular disease...
Continued tirzepatide treatment enhances weight loss but discontinuation leads to weight regain: JAMA Dr. Kamal Kant Kohli13 Dec 2023 10:45 AM ISTUSA: Withdrawing tirzepatide may lead to substantial regain of lost weight in obese;/overweight participants, whereas continued treatment augmented...
Eli Lilly Zepbound Injection for Weight Loss gets USFDA okay Roshni Dhar14 Nov 2023 3:54 PM ISTEli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Zepbound (tirzepatide) injection, an...
Tirzepatide significantly reduces predicted risk of ASCVD among patients with obesity without diabetes Niveditha Subramani13 Nov 2023 10:00 AM ISTThe results of the phase 3 trial reveal that tirzepatide treatment over 72 weeks significantly reduced the 10-year predicted risk of ASCVD versus...
